EHA 2021 | JAKARTA and JAKARTA2: OS and PFS analysis of fedratinib in myelofibrosis
John Mascarenhas, MD, Mount Sinai, New York, NY, talks on novel data from an analysis of the JAKARTA (NCT01437787) and JAKARTA2 (NCT01523171) studies, which are investigating fedratinib as first-line therapy in patients with myelofibrosis and after prior ruxolitinib. Prof. Mascarenhas reports that with a median follow-up of 19 months, the median overall survival (OS) in the JAKARTA study had not been reached, and that in JAKARTA2, the median OS was not reached with a one-year OS rate of 84%. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.
Disclosures
John Mascarenhas, MD, has received institutional research support from Incyte, Novartis, Merck, Kartos, PharmaEssentia, Forbius, Roche and CTI BIO; and has received consultancy fees from Incyte, BMS, Roche, Sierra Oncology, PharmaEssentia, CTI bio, Constellation and Kartos.
